Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D. James, Mahesh Parmar, Johann S. de Bono et al.|The Lancet|2015Cited by 2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNicholas D. James, Matthew R. Sydes, Johann S. de Bono et al.|New England Journal of Medicine|2017Cited by 1.8k
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolMatthew R. Sydes, Nicholas D. James, Melissa Spears et al.|Annals of Oncology|2018Cited by 252
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)Nicholas D. James, Jacob Tanguay, Noel W. Clarke et al.|International Journal of Cancer|2022Cited by 79
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectivenessBeth Woods, Mark Sculpher, E.G. Sideris et al.|European Urology Oncology|2018Cited by 27